Results 171 to 180 of about 77,092 (210)

Absence of xanthine oxidoreductase activity in human myocardium

Cardiovascular Research, 1991
The aim was to examine whether or not xanthine oxidase activity may be a significant source of oxygen derived free radicals in the human heart.Xanthine oxidoreductase activity of human myocardium was assayed in vitro. In addition, tests were performed to assess whether or not endogenous inhibitors of the enzyme were present in myocardial homogenates ...
T, Podzuweit, H, Beck, A, Müller, R, Bader, G, Görlach, H H, Scheld   +5 more
openaire   +4 more sources

Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation.

Biochemical Pharmacology, 2021
Proton pump inhibitors (PPI) are commonly used drugs that may increase the cardiovascular risk by mechanisms not entirely known. We examined whether the PPI omeprazole promotes vascular oxidative stress mediated by xanthine oxidoreductase (XOR) leading ...
Renato C. Nogueira, Lucas C. Pinheiro, Jéssica M. Sanches-lopes, J. M. Parente, Gustavo H Oliveira-Paula, S. O. Conde, M. Castro, J. Tanus-Santos   +7 more
semanticscholar   +1 more source

Xanthine oxidoreductase and its inhibitors: relevance for gout

Clinical Science, 2016
Xanthine oxidoreductase (XOR) is the rate-limiting enzyme in purine catabolism and converts hypoxanthine to xanthine, and xanthine into uric acid. When concentrations of uric acid exceed its biochemical saturation point, crystals of uric acid, in the form of monosodium urate, emerge and can predispose an individual to gout, the commonest form of ...
Richard O, Day, Bishoy, Kamel, Diluk R W, Kannangara, Kenneth M, Williams, Garry G, Graham   +4 more
openaire   +2 more sources

Xanthine oxidoreductase-mediated injury is amplified by upregulated AMP deaminase in type 2 diabetic rat hearts under the condition of pressure overload.

Journal of Molecular and Cellular Cardiology, 2021
BACKGROUND We previously reported that upregulated AMP deaminase (AMPD) contributes to diastolic ventricular dysfunction via depletion of the adenine nucleotide pool in a rat model of type 2 diabetes (T2DM), Otsuka Long-Evans-Tokushima Fatty rats (OLETF).
Yusuke Igaki, Masaya Tannol, Tatsuya Sato, H. Kouzu, T. Ogawa, A. Osanami, T. Yano, A. Kuno, T. Miki, Takashi Nakamura, T. Miura   +10 more
semanticscholar   +1 more source

Xanthine oxidoreductase activity in human liver disease

The American Journal of Gastroenterology, 2002
The aim of this study was to investigate the level and the form of xanthine oxidoreductase (XOR) in severely diseased human livers, to ascertain whether the modifications of the enzyme activity reported in experimental pathology also occur in human liver disease.Total, dehydrogenase, and oxidase activities of XOR were measured in samples of human liver
STIRPE F, RAVAIOLI M, BATTELLI MG, MUSIANI S, GRAZI G   +4 more
openaire   +4 more sources

Enhanced expression and activity of xanthine oxidoreductase in failing heart

Journal of Molecular and Cellular Cardiology, 2000
The molecular basis for heart failure is unknown, but oxidative stress is associated with the pathogenesis of the disease. We tested the hypothesis that the activity of xanthine oxidoreductase (XOR), a free-radical generating enzyme, increases in hypertrophied and failing heart.
J. W. de, R. G. Schoemaker, R. d. Jonge, P. Bernocchi, E. Keijzer, R. Harrison, H. S. Sharma, CECONI, Claudio   +7 more
openaire   +5 more sources

[Inhibitors of xanthine oxidoreductase].

Nihon rinsho. Japanese journal of clinical medicine, 2008
Inhibitors of xanthine oxidoreductase decrease production of uric acid, thus they act as hypouricemic drugs. Allopurinol, a prototypical xanthine oxidoreductase inhibitor, has been widely prescribed for treatment of gout and hyperuricemia. However, severe side effects of allopurinol may occur in patients with renal insufficiency.
openaire   +1 more source

Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease

Hypertension Research, 2023
Megumi Shimizu, T. Kasai, R. Naito, A. Sato, S. Ishiwata, S. Yatsu, J. Shitara, H. Matsumoto, A. Murata, Takao Kato, S. Suda, M. Hiki, M. Kuwabara, T. Murase, Takashi Nakamura, H. Daida   +15 more
semanticscholar   +1 more source

Xanthine oxidoreductase: dehydrogenase to oxidase conversion

Biochemical Society Transactions, 1997
M G, Ryan, A, Balendran, R, Harrison, A, Wolstenholme, G B, Bulkley   +4 more
openaire   +2 more sources

The xanthine oxidoreductase gene: structure and regulation

Biochemical Society Transactions, 1997
M, Terao, M, Kurosaki, S, Zanotta, E, Garattini   +3 more
openaire   +2 more sources